Efficacy of Delafloxacin Versus Moxifloxacin Against Bacterial Respiratory Pathogens in Adults With Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results From the Delafloxacin Phase 3 CABP Trial
Antimicrobial Agents and Chemotherapy - United States
doi 10.1128/aac.01949-19
Full Text
Open PDFAbstract
Available in full text
Date
December 16, 2019
Authors
Publisher
American Society for Microbiology